Compounds > pomalidomide
Page last updated: 2024-09-04

pomalidomide and oprozomib

pomalidomide has been researched along with oprozomib in 2 studies

Compound Research Comparison

Studies
(pomalidomide)		Trials
(pomalidomide)		Recent Studies (post-2010)
(pomalidomide)		Studies
(oprozomib)		Trials
(oprozomib)		Recent Studies (post-2010) (oprozomib)
62312155251548

Protein Interaction Comparison

ProteinTaxonomypomalidomide (IC50)oprozomib (IC50)
Proteasome subunit beta type-11Homo sapiens (human)0.0235
Proteasome subunit alpha type-7Homo sapiens (human)0.0235
Proteasome subunit beta type-1Homo sapiens (human)0.0235
Proteasome subunit alpha type-1Homo sapiens (human)0.0235
Proteasome subunit alpha type-2Homo sapiens (human)0.0235
Proteasome subunit alpha type-3Homo sapiens (human)0.0235
Proteasome subunit alpha type-4Homo sapiens (human)0.0235
Proteasome subunit beta type-8Homo sapiens (human)0.0385
Proteasome subunit beta type-9Homo sapiens (human)0.0235
Proteasome subunit alpha type-5Homo sapiens (human)0.0235
Proteasome subunit beta type-4Homo sapiens (human)0.0235
Proteasome subunit beta type-6Homo sapiens (human)0.0235
Proteasome subunit beta type-5Homo sapiens (human)0.0327
Proteasome subunit beta type-10Homo sapiens (human)0.0235
Proteasome subunit beta type-3Homo sapiens (human)0.0235
Proteasome subunit beta type-2Homo sapiens (human)0.0235
Proteasome subunit alpha type-6Homo sapiens (human)0.0235
Proteasome subunit alpha-type 8Homo sapiens (human)0.0235
Proteasome subunit beta type-7Homo sapiens (human)0.0235

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Berenson, JR; Chen, H; Gillespie, A; Li, M; Sanchez, E; Tang, G; Wang, CS1
Berdeja, JG; Berenson, JR; Chang, YL; Klippel, Z; Lyons, RM; Niesvizky, R; Rifkin, RM; Shah, J; Stadtmauer, EA; Usmani, S1

Reviews

1 review(s) available for pomalidomide and oprozomib

ArticleYear
Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex).
    Leukemia research, 2017, Volume: 57

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; Neovascularization, Pathologic; Oligopeptides; Thalidomide; Xenograft Model Antitumor Assays

2017

Other Studies

1 other study(ies) available for pomalidomide and oprozomib

ArticleYear
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
    Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Oligopeptides; Research Design; Retreatment; Thalidomide

2019